Amyloid Cardiomyopathy
Conditions
Keywords
Amyloid Cardiomyopathy, Enavogliflozin, Sodium-Glucose Cotransporter 2 Inhibitor
Brief summary
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.
Detailed description
Patients with a confirmed diagnosis of cardiac amyloidosis and symptomatic heart failure (NYHA class II-III) will be recruited. Participants will be randomized to receive either the study drug or placebo and will undergo baseline and 12-week assessments, including the Kansas City Cardiomyopathy Questionnaire (KCCQ), 6-minute walk test, and cardiopulmonary exercise testing. Following a 4-week washout period, participants will cross over to the alternate treatment arm (study drug or placebo) and repeat the same assessments at baseline and 12 weeks. The primary endpoint will be the change in KCCQ Clinical Summary Score (KCCQ-CSS).
Interventions
Participants will receive Enavogliflozin 0.3 mg orally once daily for 12 weeks. The drug is administered in tablet form and is taken during the first or second treatment period of a crossover design.
DRUGPlacebo
Participants will receive placebo orally once daily for 12 weeks. The drug is administered in tablet form and is taken during the first or second treatment period of a crossover design.
Sponsors
Seoul St. Mary's Hospital
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Prospective, multi-center, double-blind, randomized controlled, crossover, superiority trial
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults aged 19 years or older 2. Diagnosed with amyloid cardiomyopathy confirmed by cardiac biopsy or non-invasive imaging 3. Presence of heart failure symptoms corresponding to NYHA functional class II-III 4. Patients on stable oral diuretic use, without dose changes exceeding 50% of the previous dose, for at least 2 weeks prior to study enrollment 5. Ambulatory (able to walk) 6. Able to provide written informed consent for study participation
Exclusion criteria
1. Pregnant or breastfeeding women 2. Active infection 3. Major cardiovascular events (e.g., myocardial infarction, stroke) within the past 6 months 4. Scheduled for coronary revascularization, CRT-D implantation, atrial flutter/fibrillation ablation, or valve surgery 5. History of heart transplantation 6. Estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73 m² (calculated by CKD-EPI formula) 7. No history of cancer within the past 5 years at screening (except borderline cancers without recurrence for 2-3 years; multiple myeloma with cardiac involvement is classified as cardiac amyloidosis and is exempt) 8. Heart failure primarily caused by severe left sided valvular disease or ischemic heart disease (except if valvular disease is corrected) 9. Type 1 diabetes mellitus or insulin-dependent diabetes 10. History of ketoacidosis, complicated urinary or genital infections, or kidney stones 11. Systolic blood pressure \< 80 mmHg or symptomatic hypotension 12. Major surgery within 90 days prior to enrollment 13. Known hypersensitivity or allergic reaction to the study drug or its components 14. Moderate to severe liver impairment 15. Chronic alcohol or substance abuse 16. Residing in long-term care facilities (e.g., nursing homes) 17. Unable to understand or comply with study drug, procedures, or follow-up, or who are deemed by the investigator to be unlikely to complete the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in KCCQ-CSS from baseline to Week 12 | Baseline and Week 12 | Change in the Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) from baseline to 12 weeks after treatment initiation. The KCCQ-CSS is a patient-reported outcome measure that assesses symptom frequency and physical limitation in patients with heart failure. Scores range from 0 to 100, with higher scores indicating better symptom status and physical function (i.e., better health status). A higher change from baseline reflects an improvement in clinical status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 6-Minute Walk Distance | Baseline and Week 12 | Change in distance walked in 6 minutes from baseline to Week 12. Higher distance indicates better exercise capacity. |
| Change in log-transformed NT-proBNP levels | Baseline and Week 12 | Change in log-transformed NT-proBNP levels after 12 weeks of treatment compared to baseline |
| Change in Body Weight | Baseline and Week 12 | Change in body weight in kilograms from baseline to Week 12 |
| Change in Body Fat Percentage | Baseline and Week 12 | Change in body fat percentage from baseline to Week 12 |
| Change in Extracellular Water Ratio | Baseline and Week 12 | Change in the ratio of extracellular water to total body water from baseline to Week 12 |
| Incidence of Worsening Heart Failure Events or Death | From baseline to Week 12 during each treatment period (excluding the 4-week washout period) | Occurrence of worsening heart failure events (defined as emergency outpatient visit or unplanned hospitalization due to heart failure) or death |
Countries
South Korea
Contacts
CONTACTJong-Chan Youn, MD, PhD
CONTACTMaljoung Ahn, RN
PRINCIPAL_INVESTIGATORJong-Chan Youn, MD, PhD
Seoul St. Mary's Hospital, The Catholic University of Korea
Outcome results
None listed